(Q43774737)

26 November 2017

title

Ciprofloxacin: in vivo genotoxicity studies (English)

1 reference

26 November 2017

Herbold BA

1

1 reference

26 November 2017

Brendler-Schwaab SY

series ordinal

2

1 reference

26 November 2017

Ahr HJ

series ordinal

3

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

498

1 reference

26 November 2017

issue

1-2

1 reference

26 November 2017

page(s)

193-205

1 reference

Inhibitors of DNA topoisomerases

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Mechanism of quinolone mutagenicity in bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Study of potential in vitro and in vivo genotoxicity in hepatocytes of quinolone antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Ciprofloxacin: mammalian DNA topoisomerase type II poison in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Induction of ribonucleoside diphosphate reductase gene transcription by chemicals in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

The micronucleus test

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Chemical mutagenesis in mammals. The Chinese hamster bone marrow as an in vivo test system. Hematological findings after treatment with trenimon

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Standard protocol for the dominant lethal test on male mice set up by the work group ?dominant lethal mutations of the ad hoc Committee Chemogenetics?

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Rat hepatocyte primary cell cultures. III. Improved dissociation and attachment techniques and the enhancement of survival by culture medium

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Reliability of the hepatocyte primary culture/DNA repair test in testing of coded carcinogens and noncarcinogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

A protocol and guide for the in vitro rat hepatocyte DNA-repair assay

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II.

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

No cytogenetic effects of quinolone treatment in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Lack of effects of ciprofloxacin and the topoisomerase II inhibitors, m-AMSA and nalidixic acid, on DNA repair in cultured rat liver cells

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5718%2801%2900275-3

7 January 2021

10.1016/S1383-5718(01)00275-3

Identifiers

DOI

1 reference

26 November 2017

1 reference